Filtered By:
Drug: Prilosec
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 4 results found since Jan 2013.
Yosprala: A Fixed Dose Combination of Aspirin and Omeprazole
Cardiovascular disease is the leading cause of morbidity and mortality in the United States. Patients who survive a primary cerebrovascular or cardiovascular event are at increased risk of a subsequent occurrence. Antiplatelet therapy plays an essential role for secondary prevention in individuals with stroke, transient ischemic attack, acute or chronic artery disease, or peripheral arterial disease. Maintaining high-risk patients on low-dose aspirin therapy is a fundamental component of management. However, poor adherence, secondary to the drug’s gastrointestinal side effects, has been associated with negative cardiovas...
Source: Cardiology in Review - December 7, 2017 Category: Cardiology Tags: New Therapy Update Source Type: research
Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel
The objective of the present study was to examine the robustness of this interaction using a well-controlled study design in a population of participants free of confounders.
Source: Journal of Stroke and Cerebrovascular Diseases - February 12, 2018 Category: Neurology Authors: Eugene R. Przespolewski, Erica S. Westphal, Michelle Rainka, Nicholas M. Smith, Vernice Bates, Fran M. Gengo Source Type: research
